Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Dosage

PreclinicalBiologic

UUniversity Hospital, Clermont-Ferrand

Dosage is one of 24 biologic programs targeting Sarcopenia. It is currently in Preclinical.

1

Indications

1

Total Trials

1

Active Trials

23

Competitors

Pipeline

Status by Indication[3][1]

Indication

SarcopeniaActive, not recruiting

SarcopeniaPreclinical

Active, not recruiting

Competition

Competitive Landscape

36 competitors in Sarcopenia

#DrugCompanyPhaseTrials

Evrenzo

Calciferol

Alnylam Pharmaceuticals

Recombinant Human Erythropoietin

Andriol

Ozempic

Eldecalcitol

SShanghai Jiao Tong University Affiliated Sixth People's Hospital

Deca-Durabolin

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Comparator: Pbo

Bimagrumab

REGN1033

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

N/ANot yet recruiting

Sarcopenia

NCT06870890

Clinical

Trials by Indication[1]

Sarcopenia1 trial

Impact of Sarcopenia on Dyspnea in Patients With Asthma

Not yet recruiting·UUniversity Hospital, Clermont-Ferrand·N/A·NCT06870890·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Dosage. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dosage compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dosage. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Clermont-Ferrand company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: UUniversity Hospital, Clermont-Ferrand

Related News